Abstracts Archive - Page 1660 of 2607 - ACR Meeting Abstracts

Abstract Number: 908 • 2016 ACR/ARHP Annual Meeting
Utilization of Multiple Acute Phase Proteins and Biomarkers for Giant Cell Arteritis – Insight into Diagnosis and Clinical Complications
Blaz Burja¹, Katja Lakota¹, Tadeja Kuret¹, Polona Žigon¹, Rok Jese¹, Matija Tomsic¹, Ziga Rotar¹, Sonja Praprotnik², Tinka Svec¹, Saša Čučnik¹, Snezna Sodin Semrl¹ and Alojzija Hocevar¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose: Giant Cell Arteritis (GCA) is considered an urgent condition in Rheumatology, due to high risk of permanent vision loss and cerebro-vascular insults. No diagnostic…
Abstract Number: 909 • 2016 ACR/ARHP Annual Meeting
A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis
Bhaskar Dasgupta¹, Asad Khan¹, Dimos Merinopoulos¹, Siwalik Banerjee², Dawn Gayford³, Philip Stapleton¹, Faidra Laskou¹ and Gianina Statache¹, ¹Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Southend University Hospital NHS Foundation Trust, Wescliff-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital NHS Foundation Trust, westcliff-on-Sea, United Kingdom
Background/Purpose: It is reported that 15-25% patients with GCA present with visual complications. Sight loss (SL) in the elderly is associated with considerable morbidity. There…
Abstract Number: 910 • 2016 ACR/ARHP Annual Meeting
Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study
Amar Oza¹, Na Lu² and Hyon K. Choi³, ¹Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Boston, MA, ²Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Recent studies have shown an increase in cardiovascular and all-cause mortality in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).1 The hypothesized dual role of…
Abstract Number: 911 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
John H. Stone¹, Katie Tuckwell², Sophie Dimonaco², Micki Klearman³, Martin Aringer⁴, Daniel Blockmans⁵, Elisabeth Brouwer⁶, Maria C. Cid⁷, Bhaskar Dasgupta⁸, Juergen Rech⁹, Carlo Salvarani¹⁰, Robert F. Spiera¹¹, Sebastian H. Unizony¹, Neil Collinson² and the GiACTA Investigators, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Roche Products Ltd., Welwyn Garden City, United Kingdom, ³Genentech, South San Francisco, CA, ⁴Abteilung für Rheumatologie, Dresden, Germany, ⁵General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁶Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁸Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁹Friedrich-Alexander-University Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁰Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹¹Hospital for Special Surgery, Cornell, New York, NY
Background/Purpose: The efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-alpha inhibitor, was evaluated in patients with giant cell arteritis (GCA) in GiACTA, a randomized,…
Abstract Number: 912 • 2016 ACR/ARHP Annual Meeting
Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease
Gerald D. Levy^1,2, Craig Cheetham³, Nazia Rashid⁴ and Jiaxiao Shi³, ¹Internal Medicine/Rheumatology, Southern California Kaiser Permanente, Downey, CA, ²Rheumatology, Kaiser Permanente Southern California, Downey, CA, ³Research and Evaluation, Southern California Medical Group, Pasadena, CA, ⁴Pharmacy Analytic Services, Kaiser Permanente, Downey, CA
Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease Levy G, Cheetham C, Shi J, Rashid N Background/Purpose: To determine if urate lowering…
Abstract Number: 913 • 2016 ACR/ARHP Annual Meeting
Aggregatibacter Actinomycetemcomitans-Induced Hypercitrullination Links Periodontal Infection to Autoimmunity in Rheumatoid Arthritis
Maximilian F. Konig^1,2, Loreto Abusleme³, Jesper Reinholdt⁴, Robert J. Palmer³, Kevon Sampson¹, Ricardo P. Teles⁵, Peter A. Nigrovic⁶, Antony Rosen¹, Jeremy Sokolove⁷, Jon T. Giles⁸, Niki M. Moutsopoulos³ and Felipe Andrade¹, ¹Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ⁴Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Department of Periodontology, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁸Columbia University, College of Physicians and Surgeons, Division of Rheumatology, New York, NY
Background/Purpose: A bacterial etiology of rheumatoid arthritis (RA) has been suspected since the beginnings of modern germ theory. Recent studies implicate mucosal surfaces as sites…
Abstract Number: 914 • 2016 ACR/ARHP Annual Meeting
Longitudinal Blood Transcriptomics Uncovers Immune Networks Associated with Complications in Lupus Pregnancy
Seunghee Hong¹, Romain Banchereau¹, Marta M. Guerra², Jane E. Salmon^3,4 and Virginia Pascual¹, ¹Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX, ²Department of Medicine and Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: SLE is a systemic autoimmune disease that predominantly affects women in reproductive years. SLE pregnancies result in higher rates of adverse outcomes compared with…
Abstract Number: 915 • 2016 ACR/ARHP Annual Meeting
Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface
Tsuyoshi Shirai¹, Hiroshi Fujii¹, Tomoyuki Muto², Yuko Shirota¹, Yoko Fujita³, Tomonori Ishii¹ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Graduate School of Medicine, Sendai, Japan, ³Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Autoantibodies which recognize integral membrane proteins are generally accepted as pathogenic. However, it had been technically difficult to identify plasma membrane proteins as autoantigens…
Abstract Number: 916 • 2016 ACR/ARHP Annual Meeting
Novel Immunosignature Stratifies Patients with Rheumatoid Arthritis into Distinct Disease Sub-Groups and Predicts Response to Anti-Tnfα Therapies
Laura Magill¹, Marsilio Adriani¹, Victoria Howard², Jessica Manson², Elizabeth Jury³ and Claudia Mauri⁴, ¹University College London, London, United Kingdom, ²University College London Hospitals NHS Trust, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology Research, University College London, University College London, London, United Kingdom
Background/Purpose: Autoimmune rheumatic diseases, including rheumatoid arthritis (RA), have multifactorial pathogenesis associated with failure of immune tolerance. Advances in understanding the disease immunopathology have led…
Abstract Number: 917 • 2016 ACR/ARHP Annual Meeting
B Cells Inhibit Osteoblast Differentiation in Inflammatory Arthritis
Wen Sun^1,2, Nida Meednu³, Alex Rosenberg¹, Javier Rangel-Moreno⁴, Victor Wang³, Teresa Owen¹, Hengwei Zhang⁵, Brendan Boyce¹, Jennifer H. Anolik¹ and Lianping Xing¹, ¹University of Rochester Medical Center, Rochester, NY, ²Nanjing Medical University, Nanjing, China, ³Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is frequently associated with bone loss due to imbalanced bone resorption and formation. B cell depletion therapy (BCDT) attenuates bone erosion…
Abstract Number: 918 • 2016 ACR/ARHP Annual Meeting
Anergic B Cells May Preserve Peripheral Tolerance in Lupus-Prone Congenic Mice
Kieran Manion^1,2, Yuriy Baglaenko^1,2, Nan-Hua Chang², Nafiseh Talaei³ and Joan Wither⁴, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Genetics and Development, Krembil Research Institute, Toronto, ON, Canada, ⁴Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Anergic autoreactive B cells are thought to play a critical role in systemic lupus erythematosus (SLE), a chronic autoimmune disease where breach of tolerance…
Abstract Number: 919 • 2016 ACR/ARHP Annual Meeting
IL-17 Receptor a Signaling Impedes NF-ĸB p50/p50 Repressor and Subverts B-Cell Anergy in BXD2 Mice
Jennie Hamilton¹, Qi Wu², PingAr Yang³, Bao Luo⁴, Woongjai Won⁵, Shanrun Liu⁶, Jun Li⁷, Hui-Chen Hsu² and John D. Mountz^8,9, ¹Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Birmingham VA Medical Center, Birmingham, AL, ⁹Department of Medicine, University of Alabama at Birmingham, birmingham, AL
Background/Purpose: In autoimmune prone BXD2 mice, abnormally upregulated IL-17 acts through NF-ĸB p65 role to promote the spontaneous germinal center response and autoantibody production. Recently,…
Abstract Number: 920 • 2016 ACR/ARHP Annual Meeting
Autoantigen-Specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome
William Ruff¹, Carina Dehner², Alex Roth¹, Silvio M. Vieira¹, Cassyanne L. Aguiar^3,4, Andrew Goodman⁵, Doruk Erkan⁶ and Martin Kriegel¹, ¹Immunobiology, Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, new haven, CT, ³Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Cohen Children's Medical Center of New York/ Hofstra Northwell School of Medicine, Pediatric Rheumatology, New York, NY, ⁵Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Autoantigen-specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome William Ruff1, Carina Dehner1, Alex Roth1, Silvio M. Vieira1, Cassyanne L.…
Abstract Number: 921 • 2016 ACR/ARHP Annual Meeting
The Anti-IL-17A Antibody Secukinumab (Cosentyx®, AIN457) Diminishes the Expression of the NFκB Pathway Modulator Iκbζ
Robert Hennze¹, Thomas Schlitt¹, Thomas Peters¹, Irina Koroleva², Rebecca Torene², Xiaoyu Jiang³, Marija Curcic Djuric¹, Anis Mir¹, Frank Kolbinger¹ and Christine Huppertz¹, ¹Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, ³Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambdrige, MA
Background/Purpose: In order to better understand the IL-17A signaling pathway we have analyzed the effects of IL-17A in human primary synovial fibroblasts (SF), a…
Abstract Number: 922 • 2016 ACR/ARHP Annual Meeting
Negative Regulation of IL-17 Receptor Signaling By Regnase-1 Limits Immunopathology in a Mouse Model of Psoriatic Skin Disease
Sarah L. Gaffen¹, Leticia Monin², Nicole Ward³, Johann Gudjonsson⁴, Abhishek Garg⁵, Alicia Mathers² and Pappachan Kolattukudy⁶, ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Case Western Reserve University, Cleveland, OH, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Rheumatology/Clinical Immun, University of Pittsburgh, Pittsburgh, PA, ⁶University of Central Florida, Orlando, FL
Background/Purpose: IL-17 cytokines have emerged as drivers of autoimmunity. Indeed, the IL-17A-targeting antibody secukinumab (Cosentyx) was recently approved for treatment of plaque psoriasis, and shows…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].